Drugs / levodopa-carbidopa
levodopa-carbidopa
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02837640 | Jun 2016 → Jun 2017 | retinitis pigmentosa | Beirut Eye Specialist Hospital | Unknown | No outcome recorded |
| Phase 32 trials · 2 met primary | ||||||
| Phase 3 | NCT04006210 | Sep 2019 → Nov 2022 overdue | Parkinson disease | NeuroDerm Ltd. | Active not recruiting | Met primary |
| Phase 3 | NCT02799381 | Feb 2017 → Sep 2019 | Parkinson disease | AbbVie | Completed | Met primary |
| Phase 42 trials | ||||||
| Phase 4 | NCT00141518 | Mar 2006 → Mar 2011 | Parkinson disease | AbbVie | Completed | Mixed |
| Phase 4 | NCT00432393 | Jun 2002 → Apr 2003 | non-arteritic anterior ischemic optic neuropathy | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT00660387 Comparator | Dec 2009 → Oct 2011 | Parkinson disease | AbbVie | Completed | Met primary |
| Phase 4 | NCT02480803 Comparator | Dec 2014 → Dec 2021 | Parkinson disease | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | levodopa-carbidopa | “Participants were then randomly assigned (1:1) to 12 weeks of double-blind treatment with their optimised regimen of either subcutaneous ND0612 or oral levodopa-carbidopa, with...” PMID 38499015 ↗ Mar 2024 |
| Known as | DUOPA (carbidopa and levodopa Enteral Suspension) | “DUOPA™ (carbidopa and levodopa Enteral Suspension)” NCT00141518 ↗ |
| Known as | LCIG | “Levodopa-Carbidopa Intestinal Gel (LCIG)” NCT02799381 ↗ |
| Route | Other | “Intraduodenal Levodopa” NCT00141518 ↗ |